Vita Life SciencesASX:VLS 83 Forward PE Ratio is 0.00 as of Jul. 02, 2026. GuruFocus rates ASX:VLS with a GF Score™ of 83/100 and a GF Value™ of A$2.48 (Fairly Valued). The stock has 1 warning sign investors should review. Among 407 Drug Manufacturers companies, Vita Life Sciences ranks worse than 245700% on this metric.
Vita Life Sciences (ASX:VLS) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
Vita Life Sciences Forward PE Ratio Related Terms
Vita Life Sciences Forward PE Ratio Historical Data
* Premium members only.
The historical data trend for Vita Life Sciences's Forward PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vita Life Sciences Forward PE Ratio Chart
Vita Life Sciences Annual Data
Trend
Forward PE Ratio
Vita Life Sciences Semi-Annual Data
Forward PE Ratio
ASX:VLS vs ZTS, UTHR: Forward PE Ratio Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Vita Life Sciences's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vita Life Sciences Forward PE Ratio vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vita Life Sciences's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where Vita Life Sciences's Forward PE Ratio falls into.
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
Vita Life Sciences (ASX:VLS) has a Forward PE Ratio of 0.00 as of Jul. 02, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Vita Life Sciences and its competitors. According to the industry distribution chart, Vita Life Sciences ranks #999999 out of 407 companies in the Drug Manufacturers industry.
Is Vita Life Sciences' Forward PE Ratio too high?
Vita Life Sciences' current Forward PE Ratio is 0.00. Based on the distribution chart, Vita Life Sciences ranks #999999 out of 407 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Vita Life Sciences has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Vita Life Sciences' Forward PE Ratio compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Vita Life Sciences ranks #999999 out of 407 companies for Forward PE Ratio. This places Vita Life Sciences in the lower half of its industry. The industry median Forward PE Ratio is 17.28. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Drug Manufacturers company?
The median Forward PE Ratio among Drug Manufacturers companies is 17.28, based on 407 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on Vita Life Sciences and its competitors. For the Drug Manufacturers industry, the median Forward PE Ratio is 17.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vita Life Sciences's current Forward PE Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vita Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Vita Life Sciences (ASX:VLS) is currently considered Fairly Valued. The stock's GF Value™ is A$2.48, compared to a current price of A$2.50 — trading 0.8% above its estimated fair value. The current Forward PE Ratio is 0.00. Vita Life Sciences' overall GF Score™ is 83/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For Vita Life Sciences (ASX:VLS), the current Forward PE Ratio is 0.00 as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vita Life Sciences (ASX:VLS) Overvalued in 2026?
Based on GuruFocus' analysis, Vita Life Sciences stock appears to be overvalued.
The current stock price of A$2.50 is trading 0.8% above its estimated GF Value™ of A$2.48.
GuruFocus considers Vita Life Sciences to be Fairly Valued.
Key valuation signals for ASX:VLS:
Forward PE Ratio: 0.00
GF Value™: A$2.48 vs. price of A$2.50 (0.8% above fair value)
No single metric tells the full story. See the ASX:VLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vita Life Sciences Ltd is an Australian-based pharmaceutical and healthcare company involved in formulating, packaging, selling, and distributing vitamins and supplements. It produces a wide range of premium supplements, vitamins, minerals, herbs, and superfoods catered to all age categories and health conditions. The company markets its products through pharmacies and health food stores under the VitaHealth, VitaScience, and Herbs of Gold brands throughout the Asia-Pacific region. Vita Life Sciences has two operating segments: VMS Operational, which generates maximum revenue, and VMS Investments. Geographically, the Group generates maximum revenue from Malaysia and Singapore, and the rest from Australia, and China and Vietnam.
83GF Score
Get the complete analysis for ASX:VLS
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ASX:VLS has been successfully added to your 